Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CabOSTar maintenance cabozantinib versus best supportive care in unresectable residual osteosarcoma
2023-506229-12-00Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial in osteosarcoma (OS) comparing Cabometyx plus best supportive care with Best supportive care (2 arms). Primary endpoint: Progression-free survival assessed by blinded independent radiology committee. Started Jun 2024; status: completed.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2023-506229-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506229-12-00.